al-Juburi A Z, O'Donnell P D
Department of Urology, University of Arkansas for Medical Sciences, Little Rock.
J Ark Med Soc. 1990 Mar;86(10):383-5.
One of the more significant recent therapeutic developments in the treatment of male impotence has been intracavernous pharmacotherapy using penis self-injection technique. The intracavernous pharmacotherapy of impotence results in a relatively normal erection in most cases with minimal alteration of the anatomy, physiology, and psychosocial factor of impotence. However, early treatment success of the patient does not assure long-term success. The objective of this study was to determine the long-term utilization outcome of intracavernous pharmacotherapy in the management of impotence. Of 103 enrolled in the study, 50 patients (49%) were actively using the injection treatment method after 18 months. There were no significant difference in mean age of those patients who discontinued from those who continued to use intracavernous therapy. Of the 53 patients (51%) who discontinued intracavernous therapy, 33 patients (62%) were unsatisfied with the results, nine patients (17%) were unsatisfied with the methodology, eight patients (15%) developed penile complications, and three patients (6%) had improvement of sexual function. Thirty-four (69%) of those who discontinued therapy elected an alternative form of therapy and 16 patients (30%) were not interested in any further treatment. While it is difficult to assess the many factors involved in the outcome of therapy for impotence, the assessment of long-term intracavernous therapy utilization provides a relatively low risk means for clinical evaluation of the therapeutic value of pharmacotherapy for the individual as well as a clinical indication of the sexual function needs of the patient.
阴茎海绵体内药物治疗结合阴茎自我注射技术是近期男性勃起功能障碍治疗领域较为重要的一项治疗进展。阴茎海绵体内药物治疗在大多数情况下能使阴茎相对正常勃起，对勃起功能障碍的解剖、生理和心理社会因素影响极小。然而，患者早期治疗成功并不意味着能长期成功。本研究的目的是确定阴茎海绵体内药物治疗在勃起功能障碍管理中的长期应用效果。在参与研究的103名患者中，18个月后有50名患者（49%）仍在积极使用注射治疗方法。停止使用阴茎海绵体内治疗的患者与继续使用者的平均年龄无显著差异。在停止阴茎海绵体内治疗的53名患者（51%）中，33名患者（62%）对治疗结果不满意，9名患者（17%）对治疗方法不满意，8名患者（15%）出现阴茎并发症，3名患者（6%）性功能有所改善。停止治疗的患者中有34名（69%）选择了其他治疗方式，16名患者（30%）对进一步治疗不感兴趣。虽然很难评估影响勃起功能障碍治疗结果的诸多因素，但对阴茎海绵体内长期治疗应用情况的评估为临床评估药物治疗对个体的治疗价值提供了一种风险相对较低的方法，同时也为患者性功能需求提供了临床指征。
